Last reviewed · How we verify
aminophylline hydrate
At a glance
| Generic name | aminophylline hydrate |
|---|---|
| Also known as | Kyophyllin® Injection 2.5%, FK05 |
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Chronic obstructive pulmonary disease
- Upper respiratory tract infection
- Nasopharyngitis
- Pyrexia
- Haemoptysis
- Cough
- Productive cough
- Diarrhoea
- Dizziness
- Palpitations
- Coronary artery disease
- Abdominal pain
Key clinical trials
- Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD
- Theophylline for Treatment of Pseudohypoparathyroidism (PHASE2)
- Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old (PHASE2)
- Theophylline Treatment for Pseudohypoparathyroidism (PHASE2)
- Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (NA)
- Reverse Triple Negative Immune Resistant Breast Cancer (PHASE2)
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (PHASE3)
- Prevention of Cisplatin-induced Nephrotoxicity (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aminophylline hydrate CI brief — competitive landscape report
- aminophylline hydrate updates RSS · CI watch RSS
- Organon and Co portfolio CI